check_circleStudy Completed
Age-related macular degeneration (AMD), Central retinal vein occlusion (CRVO), Diabetic Macular Edema (DME)
Bayer Identifier:
18498
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
Trial purpose
The primary objective of this study is to measure physician knowledge and understanding of the key safety information contained in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
Key Participants Requirements
Sex
BothAge
NaN - N/ATrial summary
Enrollment Goal
99Trial Dates
February 2016 - May 2016Phase
N/ACould I Receive a placebo
NoProducts
Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)Accepts Healthy Volunteer
YesWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Canada |
Primary Outcome
- Knowledge and understanding of key information contained in the aflibercept educational materials: the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monographThe source of information for the study will be self-reported data collected from physicians using standard questionnaires with closed-ended response choices.date_rangeTime Frame:Up to 8 weeks after the start of data collectionenhanced_encryptionNoSafety Issue:
Secondary Outcome
- Investigation whether physicians have received the educational materialsDescriptive results assessing Number and percentage (%) of physiciansdate_rangeTime Frame:up to 6 monthenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A